Natera (NASDAQ:NTRA) PT Raised to $100.00 at The Goldman Sachs Group

Natera (NASDAQ:NTRA) had its price objective raised by The Goldman Sachs Group from $90.00 to $100.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other equities research analysts also recently weighed in on NTRA. Sanford C. Bernstein upgraded Natera from a market perform rating to an outperform rating and set a $120.00 target price for the company in a report on Friday, April 5th. Raymond James lowered shares of Natera from a strong-buy rating to an outperform rating and increased their target price for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. Canaccord Genuity Group lifted their price target on shares of Natera from $87.00 to $100.00 and gave the company a buy rating in a research note on Thursday, February 29th. Stephens reissued an overweight rating and set a $78.00 price objective on shares of Natera in a research report on Tuesday, January 30th. Finally, Piper Sandler boosted their target price on Natera from $70.00 to $110.00 and gave the company an overweight rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $86.40.

Natera Stock Down 3.4 %

Shares of NASDAQ NTRA opened at $87.28 on Monday. Natera has a 52-week low of $36.90 and a 52-week high of $98.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The company’s 50 day moving average price is $85.74 and its 200-day moving average price is $65.57. The company has a market capitalization of $10.54 billion, a P/E ratio of -23.03 and a beta of 1.37.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Equities analysts forecast that Natera will post -2.35 earnings per share for the current year.

Insider Activity at Natera

In other Natera news, insider John Fesko sold 2,358 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $65.09, for a total transaction of $153,482.22. Following the transaction, the insider now directly owns 108,494 shares in the company, valued at approximately $7,061,874.46. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Daniel Rabinowitz sold 35,307 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total value of $2,651,202.63. Following the transaction, the insider now owns 204,218 shares in the company, valued at approximately $15,334,729.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John Fesko sold 2,358 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $65.09, for a total value of $153,482.22. Following the sale, the insider now directly owns 108,494 shares of the company’s stock, valued at $7,061,874.46. The disclosure for this sale can be found here. Insiders have sold a total of 453,293 shares of company stock valued at $36,453,056 over the last 90 days. Insiders own 9.42% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. RiverPark Advisors LLC purchased a new position in shares of Natera in the 4th quarter worth about $27,000. Principal Securities Inc. bought a new stake in Natera in the fourth quarter worth about $32,000. Harvest Fund Management Co. Ltd purchased a new position in Natera in the third quarter valued at about $44,000. Oliver Lagore Vanvalin Investment Group grew its position in shares of Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 389 shares during the period. Finally, CWM LLC increased its stake in shares of Natera by 224.4% during the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after purchasing an additional 911 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.